Welcome to LookChem.com Sign In|Join Free

CAS

  • or

139332-61-9

Post Buying Request

139332-61-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

139332-61-9 Usage

General Description

(+)-S-Arotinolol is a beta-adrenergic antagonist and calcium channel blocker that is used as a medication for the treatment of high blood pressure, angina, and arrhythmias. It works by blocking the action of adrenaline on the muscles and blood vessels, leading to decreased heart rate and relaxed blood vessels, which in turn lowers blood pressure. This chemical has been shown to be effective in controlling the symptoms of hypertension and reducing the risk of cardiovascular events. However, it may also cause side effects such as dizziness, fatigue, and nausea. (+)-S-Arotinolol is typically administered orally in the form of tablets or capsules, and its dosage should be carefully monitored and adjusted by a healthcare professional to ensure its efficacy and safety.

Check Digit Verification of cas no

The CAS Registry Mumber 139332-61-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,9,3,3 and 2 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 139332-61:
(8*1)+(7*3)+(6*9)+(5*3)+(4*3)+(3*2)+(2*6)+(1*1)=129
129 % 10 = 9
So 139332-61-9 is a valid CAS Registry Number.

139332-61-9Relevant articles and documents

Preparation method of arotinolol hydrochloride

-

, (2021/07/09)

The invention relates to the technical field of medicines, particularly provides a preparation method of arotinolol hydrochloride, and relates to the technical field of medicines. The preparation method of the arotinolol hydrochloride, provided by the invention, comprises the following steps: (1) enabling tetrahydrofuran, 2-formamide-5-(2-sulfydryl-1, 3-thiazole-4-yl)-thiophene, water, sodium bicarbonate and epoxy chloropropane to react to generate an intermediate product C181101170-I03; (2) carrying out a reaction on absolute ethyl alcohol, C181101170-I03 and tert-butylamine, so as to obtain an intermediate product C181101170-I02; (3) subjecting methanol, ethyl acetate, C181101170-I02 and concentrated hydrochloric acid to a reaction, and obtaining an arotinolol hydrochloride crude product; and (4) treating the arotinolol hydrochloride crude product with DMSO and acetone to obtain arotinolol hydrochloride. The product arotinolol hydrochloride obtained by the method is high in yield, high in purity and small in impurity, the purity of the product can be well controlled, and the method is suitable for industrial production.

Refinement method of arotinolol hydrochloride

-

Paragraph 0018; 0020; 0022; 0024, (2018/02/04)

The invention relates to a refinement method of arotinolol hydrochloride and belongs to the field of chemical medicines. The refinement method is characterized in that crude arotinolol hydrochloride is added to a system containing ethyl acetate, methanol and pure water, subjected to an alkali recovery operation under a weak alkaline condition, then pulped and purified, and free alkaline arotinolol with higher purity is obtained; arotinolol forms salt in an alcoholic solution, and refined arotinolol hydrochloride is obtained. The method is simple to operate, the yield is relatively high, and industrial production is facilitated.

ANTIHYPERTENSIVE THERAPY

-

, (2009/09/08)

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 139332-61-9